Nuveen California Select Tax-Free Income Portfolio faces significant headwinds as its total asset base has eroded from $101.5M in 2020Q4 to $88.8M by 2024Q4, signaling potential difficulties in maintaining historical interest-generating capacity.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
Immix Biopharma NASDAQ: IMMX reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy.
Benchmark NXC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nuveen California Select Tax-Free Income Portfolio (NXC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.29 | $83.01M | 37.97 | -28.59% | 60.71% | 2.54% | — | |
| $1178.87 | $182.72B | 33.28 | 18.32% | 23% | 10.06% | 1.72% | |
| $27.08 | $12B | -16.93 | 4.75% | -1.12% | -0.59% | 3.07% | |
| $108.41 | $23.23B | 11.72 | 3.12% | 28.4% | 17.96% | 4.71% | |
| $33.73 | $17.53B | 37.07 | 3.52% | 9.56% | 6.35% | 3.93% | |
| $181.44 | $286.18B | 17.79 | 14.48% | 26.15% | 17.15% | 2.28% |
Nuveen California Select Tax-Free Income Portfolio (NXC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NXC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nuveen California Select Tax-Free Income Portfolio (NXC) stock FAQ — growth, dividends, profitability & financials explained
Nuveen California Select Tax-Free Income Portfolio (NXC) reported $6.1M in revenue over the trailing twelve months. Revenue was $1.0M in fiscal year 2024. That is 0% more than the $1.0M of fiscal year 2012.
Nuveen California Select Tax-Free Income Portfolio (NXC) revenue fell by 28.6% in fiscal year 2024, compared with the prior fiscal year.
Yes. Nuveen California Select Tax-Free Income Portfolio (NXC) earned $7.3M in net income over the trailing twelve months (a 121.2% net margin).
Nuveen California Select Tax-Free Income Portfolio (NXC) had a return on equity (ROE) of 2.5% in fiscal year 2024. That is below the market's typical 10-15%.
